These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3264846)

  • 1. [Augmentation of lymphokine-activated killer (LAK) cell activity by combination of low dose interleukin 2 and several kinds of biological response modifiers (BRMs)].
    Ohnishi H; Okuno K; Nakamura T; Nakamura Y; Yasutomi M
    Nihon Gan Chiryo Gakkai Shi; 1988 Oct; 23(10):2539-45. PubMed ID: 3264846
    [No Abstract]   [Full Text] [Related]  

  • 2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
    J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B; Rees RC
    Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.
    Crump WL; Owen-Schaub LB; Grimm EA
    Cancer Res; 1989 Jan; 49(1):149-53. PubMed ID: 2783241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma.
    Wang Y; Qian XJ; Hadley HR; Lau BH
    Mol Biother; 1992 Sep; 4(3):143-6. PubMed ID: 1445669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
    J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
    Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.